Ulcerative colitis-Disease Activity Index) ou « score Mayo ,
, Il s'agit du score le plus utilisé à ce jour. La RCH est dite active quand le score est entre 6 et 12
,
, L'item « friabilité » a disparu car non reproductible. Ce score a été récemment validé
Traité de Gastroentérologie. Flammarion, 2005. ,
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, Gastroenterology, vol.142, issue.1, pp.46-54, 2012. ,
Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD). Dig Liver Dis, vol.45, pp.89-94, 2013. ,
DOI : 10.1016/j.dld.2012.09.005
URL : https://hal.archives-ouvertes.fr/hal-01701899
Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD), Gut, vol.39, issue.5, pp.690-697, 1996. ,
Inflammatory bowel disease: pathogenesis, World J Gastroenterol, vol.20, issue.1, pp.91-100, 2014. ,
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis, J Crohns Colitis, vol.4, issue.1, pp.7-27, 2010. ,
Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel, Aliment Pharmacol Ther, vol.15, issue.10, pp.1009-1025, 2003. ,
Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines, J Crohns Colitis, vol.7, issue.7, pp.556-85, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01704202
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis, J Crohns Colitis, vol.6, issue.10, pp.965-90, 2012. ,
Clinical, endoscopic, and histological differentiations between Crohn's disease and intestinal tuberculosis, Am J Gastroenterol, vol.105, issue.3, pp.642-51, 2010. ,
Cytomegalovirus colitis complicating inflammatory bowel disease, Am J Gastroenterol, vol.101, issue.12, pp.2857-65, 2006. ,
Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease, Aliment Pharmacol Ther, vol.23, issue.8, pp.1097-104, 2006. ,
Risk of colorectal cancer in patients with ulcerative colitis: a metaanalysis of population-based cohort studies, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.10, issue.6, pp.639-684, 2012. ,
,
, Rev Gastroenterol México, vol.80, issue.1, pp.74-106, 2015.
High lifetime risk of cancer in primary sclerosing cholangitis, J Hepatol, vol.50, issue.1, pp.158-64, 2009. ,
Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III), J Crohns Colitis, vol.8, issue.1, pp.31-44, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-00829286
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease, J Crohns Colitis, vol.5, issue.5, pp.477-83, 2011. ,
Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED), Endoscopy, vol.45, issue.11, pp.936-979, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01701888
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD, Gastrointest Endosc, vol.60, issue.4, pp.505-517, 2004. ,
Predictability of the postoperative course of Crohn's disease, Gastroenterology, vol.99, issue.4, pp.956-63, 1990. ,
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis, Gastroenterology, vol.132, issue.2, pp.763-86, 2007. ,
Reliability and initial validation of the ulcerative colitis endoscopic index of severity, Gastroenterology, vol.145, issue.5, pp.987-95, 2013. ,
Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease, Aliment Pharmacol Ther, vol.33, issue.3, pp.304-316, 2011. ,
Calprotectin or Lactoferrin: Do They Help, Dig Dis Basel Switz, vol.34, issue.1-2, pp.98-104, 2016. ,
Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage, Gut, vol.58, issue.6, pp.859-68, 2009. ,
Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease, Inflamm Bowel Dis, vol.20, issue.4, pp.742-56, 2014. ,
Diagnostic accuracy of fecal lactoferrin for inflammatory bowel disease: a meta-analysis, Int J Clin Exp Pathol, vol.8, issue.10, pp.12319-12351, 2015. ,
Calprotectin, a faecal marker of organic gastrointestinal abnormality, Lancet Lond Engl, vol.356, issue.9244, pp.1783-1787, 2000. ,
Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease, Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver, vol.41, issue.1, pp.56-66, 2009. ,
Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome, Clin Chem Lab Med, vol.46, issue.9, pp.1275-80, 2008. ,
Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis, BMJ, vol.341, p.3369, 2010. ,
Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.12, issue.2, pp.253-62, 2014. ,
Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des, Affections Inflammatoires Digestives. Gut, vol.35, issue.2, pp.231-236, 1994. ,
DOI : 10.1136/gut.35.2.231
URL : https://gut.bmj.com/content/35/2/231.full.pdf
Faecal calprotectin: Management in inflammatory bowel disease, World J Gastrointest Pathophysiol, vol.6, issue.4, pp.203-212, 2015. ,
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease, Inflamm Bowel Dis, vol.18, issue.12, pp.2218-2242, 2012. ,
A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease, J Crohns Colitis, vol.7, issue.12, pp.641-51, 2013. ,
Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies, Inflamm Bowel Dis, vol.18, issue.10, pp.1894-1903, 2012. ,
Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease, Inflamm Bowel Dis, vol.14, issue.10, pp.1392-1400, 2008. ,
DOI : 10.1002/ibd.20490
Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease, Scand J Gastroenterol, vol.47, issue.5, pp.528-565, 2012. ,
Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease, Br J Surg, vol.96, issue.6, pp.663-74, 2009. ,
DOI : 10.1002/bjs.6593
Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease, Am J Gastroenterol, vol.110, issue.6, pp.865-72, 2015. ,
Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis, Am J Gastroenterol, vol.104, issue.3, pp.673-681, 2009. ,
Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis, vol.16, pp.1091-1093, 2010. ,
DOI : 10.1002/ibd.21136
A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease, Aliment Pharmacol Ther, vol.37, issue.6, pp.613-634, 2013. ,
Aminosalicylates for induction of remission or response in Crohn's disease, Cochrane Database Syst Rev, issue.12, p.8870, 2010. ,
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.10, p.544, 2012. ,
Second European evidencebased consensus on the diagnosis and management of ulcerative colitis part 2: current management, J Crohns Colitis, vol.6, issue.10, pp.991-1030, 2012. ,
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, vol.10, p.67, 2015. ,
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.9, p.478, 2012. ,
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, Gut, vol.54, issue.8, pp.1121-1126, 2005. ,
Methotrexate for maintenance of remission in Crohn's disease, Cochrane Database Syst Rev, issue.4, p.6884, 2009. ,
Methotrexate for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.8, p.7560, 2015. ,
Cyclosporine in severe ulcerative colitis refractory to steroid therapy, N Engl J Med, vol.330, issue.26, pp.1841-1846, 1994. ,
DOI : 10.1056/nejm199406303302601
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis, Gastroenterology, vol.146, issue.2, pp.392-400, 2014. ,
DOI : 10.1053/j.gastro.2013.10.052
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet Lond Engl, vol.371, issue.9613, pp.660-667, 2008. ,
, Quand débuter un traitement anti-TNF ?
, , 2016.
, Chloé Maréchal 1,2 ; Isabelle Aimone-Gastin 4
, Laurent Peyrin-Biroulet, vol.1, issue.2
,
, Abbreviations used in this paper: IBD: Inflammatory Bowel Disease UC: Ulcerative colitis CD: Crohn disease FC: Fecal Calprotectin Disclosures: LPB: Consulting fees from Merck
Inflammatory bowel disease: clinical aspects and established and evolving therapies, Lancet, vol.369, pp.1641-57, 2007. ,
Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease, J Crohns Colitis, vol.5, pp.477-83, 2011. ,
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease, Inflamm Bowel Dis, pp.1295-301, 2009. ,
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial, Lancet Lond Engl, vol.371, pp.660-667, 2008. ,
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial, Gastroenterology, vol.142, pp.1102-1113, 2012. ,
Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, vol.353, pp.2462-76, 2005. ,
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, Am J Gastroenterol, vol.110, pp.1324-1362, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01191653
European evidence based consensus for endoscopy in inflammatory bowel disease, J Crohns Colitis, vol.7, pp.982-1018, 2013. ,
Minor adverse events postcolonoscopy, Can J Gastroenterol Hepatol, vol.28, p.606, 2014. ,
Colonoscopic perforations: a review of 30,366 patients, Surg Endosc, vol.21, pp.994-1001, 2007. ,
Patient acceptance of CT colonography and conventional colonoscopy: prospective comparative study in patients with or suspected of having colorectal disease, Radiology, vol.222, pp.337-382, 2002. ,
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis, Am J Gastroenterol, vol.110, pp.802-821, 2015. ,
Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring, Gut, vol.62, pp.1806-1822, 2013. ,
Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease, Inflamm Bowel Dis, vol.20, pp.742-56, 2014. ,
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices, Am J Gastroenterol, vol.103, pp.162-171, 2008. ,
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse, Inflamm Bowel Dis, vol.15, pp.1190-1198, 2009. ,
Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study, Scand J Gastroenterol, vol.27, pp.793-801, 1992. ,
111Indium autologous granulocytes in the detection of inflammatory bowel disease, Gut, vol.26, pp.955-60, 1985. ,
Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity, Inflamm Bowel Dis, vol.20, pp.1407-1422, 2014. ,
Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies, Inflamm Bowel Dis, vol.18, pp.1894-1903, 2012. ,
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease, Inflamm Bowel Dis, vol.18, pp.2218-2242, 2012. ,
Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy, Inflamm Bowel Dis, vol.19, pp.2111-2118, 2013. ,
A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease, Aliment Pharmacol Ther, vol.37, pp.613-634, 2013. ,
Fecal calprotectin variability in Crohn's disease, Inflamm Bowel Dis, vol.16, pp.1091-1093, 2010. ,
Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery, Gastroenterology, vol.148, pp.938-985, 2015. ,
Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease, Am J Gastroenterol, vol.110, pp.865-72, 2015. ,
Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy, J Clin Gastroenterol, 2015. ,
Factors affecting compliance in colorectal cancer screening. Results of a study performed in Ballarat, Med J Aust, vol.144, pp.621-624, 1986. ,
Patient compliance with colorectal cancer screening in general practice, Br J Gen Pract J R Coll Gen Pract, vol.42, pp.18-20, 1992. ,
Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review, Inflamm Bowel Dis, vol.19, pp.1528-1561 ,
A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases, Adv Ther, vol.32, pp.983-1028, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01667551
Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations, J Manag Care Pharm JMCP, vol.12, pp.239-284, 2006. ,
The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes, PloS One, vol.7, p.33839, 2012. ,
Adherence to long-term therapies: evidence for action, J Nurs Scholarsh Off Publ Sigma Theta Tau Int Honor Soc Nurs Sigma Theta Tau, vol.35, p.207, 2003. ,
Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review, Am J Gastroenterol, vol.105, pp.525-564, 2010. ,
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-tosevere Inflammatory Bowel Disease. Dig Liver Dis, 2016. ,
Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method, Clin Chem Lab Med, vol.5, pp.825-856, 2013. ,
A systematic review of the effects of home blood pressure monitoring on medication adherence, J Clin Hypertens Greenwich Conn, vol.8, pp.174-80, 2006. ,
Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review, PloS One, vol.10, p.145076, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01257916
Organized colorectal cancer screening programmes: how to optimize efficiency among general practitioners, Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP, vol.20, issue.1, pp.26-32, 2011. ,